- Home
- ARTV
as 05-09-2025 3:31pm EST
Stocks
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 61.9M | IPO Year: | 2024 |
| Target Price: | $20.00 | AVG Volume (30 days): | 212.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.78 - $17.31 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | -99.25% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ARTIVA BIOTHERAPEUTICS INC News
ARTV Breaking Stock News: Dive into ARTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
GlobeNewswire
11 days ago
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
MT Newswires
a month ago
Artiva Biotherapeutics Names New Chief Medical Officer
GlobeNewswire
a month ago
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
GlobeNewswire
a month ago
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
2 months ago
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
3 months ago
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
GlobeNewswire
3 months ago
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
Compare ARTV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARTV ARTIVA BIOTHERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.